Direct oral anticoagulants in patients with chronic kidney disease: patient selection and special considerations

Many patients with chronic kidney disease (CKD) receive anticoagulation or antiplatelet therapy due to atrial fibrillation, coronary artery disease, thromboembolic disease, or peripheral artery disease. The treatment usually includes vitamin K antagonists (VKAs) and/or platelet aggregation inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales: Lutz, Jens, Jurk, Kerstin, Schinzel, Helmut
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473496/
https://www.ncbi.nlm.nih.gov/pubmed/28652799
http://dx.doi.org/10.2147/IJNRD.S105771

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473496/
https://www.ncbi.nlm.nih.gov/pubmed/28652799
http://dx.doi.org/10.2147/IJNRD.S105771

Ejemplares similares